Caramiphen

Caramiphen
Clinical data
Trade names	Carafen
ATC code	None;
Identifiers
	IUPAC name 2-(Diethylamino)ethyl 1-phenylcyclopentanecarboxylate;
CAS Number	77-22-5;
PubChem CID	6472;
ChemSpider	6228;
UNII	97J7NP0XJY;
ChEMBL	ChEMBL61946;
CompTox Dashboard (EPA)	DTXSID0022729 ;
ECHA InfoCard	100.000.922
Chemical and physical data
Formula	C18H27NO2
Molar mass	289.419 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(OCCN(CC)CC)C2(c1ccccc1)CCCC2;
	InChI InChI=1S/C18H27NO2/c1-3-19(4-2)14-15-21-17(20)18(12-8-9-13-18)16-10-6-5-7-11-16/h5-7,10-11H,3-4,8-9,12-15H2,1-2H3; Key:OFAIGZWCDGNZGT-UHFFFAOYSA-N;

Caramiphen is an anticholinergic drug used in the treatment of Parkinson's disease.^[1] In combination with phenylpropanolamine it is used as a cough suppressant and nasal decongestant to treat symptoms associated with respiratory illnesses such as cold, allergies, hay fever, and sinusitis.^[2] It was added to the British National Formulary in 1963, with a dosage of 10 to 20 mg. Side effects include nausea, dizziness, and drowsiness.^[3]

Quick facts Clinical data, Trade names ...

Close

It binds to the sigma-1 receptor with an IC₅₀ value of 25 nM.^[4]

References